Growth hormone deficiency – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:23:45 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Growth hormone deficiency – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study of Lonapegsomatrin and Somatropin in Children and Adolescents with Short Stature or Growth Failure due to Turner Syndrome, SHOX Deficiency, SGA, or Idiopathic Short Stature https://clinicaltrials.eu/trial/study-of-lonapegsomatrin-and-somatropin-in-children-and-adolescents-with-short-stature-or-growth-failure-due-to-turner-syndrome-shox-deficiency-sga-or-idiopathic-short-stature/ Wed, 29 Apr 2026 15:09:09 +0000 https://clinicaltrials.eu/trial/study-of-lonapegsomatrin-and-somatropin-in-children-and-adolescents-with-short-stature-or-growth-failure-due-to-turner-syndrome-shox-deficiency-sga-or-idiopathic-short-stature/ This study is being conducted to evaluate the efficacy and safety of lonapegsomatropin compared to somatropin. The research focuses on children and adolescents who experience growth failure or short stature, which means they are shorter than expected for their age. These conditions may be caused by several different disorders, such as Turner Syndrome, SHOX Deficiency, being small for gestational age, or idiopathic short stature, which is when short height occurs without a known medical cause.

Participants in the study will receive either lonapegsomatropin or somatropin through a subcutaneous injection, which is a method of delivering medication into the fatty layer just under the skin. The goal is to compare a weekly injection of the new medication to the daily use of the standard treatment. During the course of the study, height and growth progress will be monitored over a period of time to see how the different treatments affect development.

]]> Study on the Effects of Somapacitan and Somatropin in Children with Growth Hormone Deficiency https://clinicaltrials.eu/trial/study-on-the-effects-of-somapacitan-and-somatropin-in-children-with-growth-hormone-deficiency/ Wed, 29 Apr 2026 14:28:34 +0000 https://clinicaltrials.eu/trial/study-on-the-effects-of-somapacitan-and-somatropin-in-children-with-growth-hormone-deficiency/ This clinical trial is focused on studying children with a condition known as Growth Hormone Deficiency. This condition occurs when the body does not produce enough growth hormone, which is important for growth and development. The study is comparing two treatments: Somapacitan, which is given once a week, and Norditropin®, which is administered daily. Both treatments are solutions for injection, delivered using a pen-injector device.

The purpose of the study is to compare the effects of these two treatments on the growth of children with this deficiency. Participants will receive either the weekly or daily treatment over a period of time. The study will monitor how well the children grow in height and will also look at other factors like changes in bone age and certain blood markers. The study will last for several weeks, with regular visits to check on the children’s progress.

Throughout the study, the safety of the treatments will be closely monitored. This includes checking for any changes in blood sugar levels and other health indicators. The study aims to provide valuable information on the effectiveness and safety of Somapacitan compared to Norditropin® in helping children with Growth Hormone Deficiency grow and develop properly.

]]> Long-Term Safety Study of LUM-201 (Ibutamoren Mesilate) in Children with Growth Hormone Deficiency https://clinicaltrials.eu/trial/long-term-safety-study-of-lum-201-ibutamoren-mesilate-in-children-with-growth-hormone-deficiency/ Wed, 29 Apr 2026 14:26:44 +0000 https://clinicaltrials.eu/trial/long-term-safety-study-of-lum-201-ibutamoren-mesilate-in-children-with-growth-hormone-deficiency/ This clinical trial is focused on children with Idiopathic Growth Hormone Deficiency, a condition where the body does not produce enough growth hormone, leading to slower growth in children. The study is examining the long-term safety of a treatment called LUM-201, which contains the active substance Ibutamoren Mesilate. This medication is taken in the form of a tablet.

The purpose of the study is to monitor the safety of LUM-201 over an extended period. Participants in the study will continue their treatment and be regularly monitored by healthcare professionals. The study will track various health indicators, such as growth hormone levels and changes in height and weight, every six months. Additionally, the study will assess changes in bone age compared to chronological age annually.

Throughout the study, participants will have regular check-ups to ensure their well-being and to observe any side effects or changes in their health. The study aims to provide valuable information on the long-term use of LUM-201 in managing Idiopathic Growth Hormone Deficiency in children.

]]> Study on Growth Hormone Deficiency: Comparing Effects of Continuing vs. Stopping Somatropin Treatment in Pubertal Children with Isolated Growth Hormone Deficiency https://clinicaltrials.eu/trial/study-on-growth-hormone-deficiency-comparing-effects-of-continuing-vs-stopping-somatropin-treatment-in-pubertal-children-with-isolated-growth-hormone-deficiency/ Wed, 29 Apr 2026 14:24:42 +0000 https://clinicaltrials.eu/trial/study-on-growth-hormone-deficiency-comparing-effects-of-continuing-vs-stopping-somatropin-treatment-in-pubertal-children-with-isolated-growth-hormone-deficiency/ This clinical trial is focused on studying Growth Hormone Deficiency (GHD), a condition where the body does not produce enough growth hormone, which is important for growth and development. The trial will use a treatment called somatropin, which is a form of human growth hormone made in the laboratory. Several brands of somatropin will be used in this study, including NutropinAq, Saizen, Omnitrope, Humatrope, Norditropin FlexPro, and Genotropin MiniQuick. These are all solutions for injection that help to increase growth hormone levels in the body.

The purpose of the study is to compare the effects of continuing versus stopping growth hormone treatment in children who have reached puberty and have shown a reversal of their growth hormone deficiency. The study will involve children who have already stopped taking growth hormone for at least six weeks and have shown improvement in their condition. Participants will be divided into two groups: one group will continue receiving growth hormone treatment, while the other group will not. The main goal is to see how these different approaches affect the children’s final height as they grow into adulthood.

Throughout the study, participants will be monitored to assess their growth and development. This will include measuring their height and comparing it to their expected adult height based on their parents’ heights. The study will also look at other factors related to growth, such as bone health and certain blood markers. The trial is expected to continue until early 2026, providing valuable information on the best approach to managing growth hormone deficiency in children during puberty.

]]>